Chromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer

Chen,Wang  Yang; Zhang,Xian  Yu; Liu,Tong; Liu,Yang; Zhao,Ya  Shuang; Pang,Da

doi:10.3892/ol.2016.5529

Chromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer

Authors:
- Wang Yang Chen
- Xian Yu Zhang
- Tong Liu
- Yang Liu
- Ya Shuang Zhao
- Da Pang
View Affiliations

Affiliations: Heilongjiang Academy of Medical Sciences, Harbin, Heilongjiang 150044, P.R. China, Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Epidemiology, Public Health College, Harbin Medical University, Harbin, Heilongjiang 150040, P.R. China
Published online on: December 23, 2016 https://doi.org/10.3892/ol.2016.5529
Pages: 1149-1156
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycomb group (PcG) complexes modify histones to silence tumor suppressor genes, which exhibit an important function in tumorigenesis and progression. The chromobox (Cbx) protein family is a critical component of PcG-mediated repression. Cbx2, a member of the Cbx protein family, is hypothesized to exhibit a vital role in breast cancer. In the present study, immunohistochemical analysis using tissue microarrays was performed to determine the levels of Cbx2 protein expression in breast cancer. The association between Cbx2 expression and the clinical features and prognosis of 455 breast cancer patients was analyzed. In addition, the efficacy of Taxol was evaluated by comparing the survival of patients with high or low Cbx2 expression. The results revealed that Cbx2 expression was higher in cancer tissues compared with adjacent normal tissues. Furthermore, high Cbx2 expression was significantly associated with large tumor size, lymph node metastasis, high TNM stage and positive human epidermal growth factor receptor‑2 (HER‑2) status. Patients with high Cbx2 expression also exhibited a shorter mean overall survival (OS) time (74.37 months) compared with patients with low Cbx2 expression (77.37 months). Univariate analysis indicated that high Cbx2 expression increased the risk of mortality by 1.826‑fold compared with low Cbx2 expression [hazard ratio (HR), 1.826; 95% confidence interval (CI), 1.069‑3.116; P=0.027]. Among patients with high Cbx2 expression, the mean OS time of individuals treated with Taxol (71.01 months) was lower compared with patients that had not received Taxol treatment (78.43 months; log‑rank test statistic, 13.03; P<0.001). However, no significant difference in OS time was identified in the low expression group. The results of the current study revealed that Cbx2 may present a novel biomarker for predicting the prognosis of breast cancer patients. Cbx2 may also represent a potential target for treatment due to its important function in Taxol treatment responses.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ali AM, Provenzano E, Bartlett JM, Abraham J, Driver K, Munro AF, Twelves C, Poole CJ, Hiller L, Dunn JA, et al: Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. Int J Cancer. 133:1470–1478. 2013. View Article : Google Scholar : PubMed/NCBI
4	Liu R, Lv QL, Yu J, Hu L, Zhang LH, Cheng Y and Zhou HH: Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 151:607–618. 2015. View Article : Google Scholar : PubMed/NCBI
5	Krishnan P, Ghosh S, Wang B, Li D, Narasimhan A, Berendt R, Graham K, Mackey JR, Kovalchuk O and Damaraju S: Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics. 16:7352015. View Article : Google Scholar : PubMed/NCBI
6	Boccardo F, Rubagotti A, Nuzzo PV, Argellati F, Savarino G, Romano P, Damonte G, Rocco M and Profumo A: Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery. Int J Cancer. 137:2394–2402. 2015. View Article : Google Scholar : PubMed/NCBI
7	Sparmann A and van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 6:846–856. 2006. View Article : Google Scholar : PubMed/NCBI
8	Shao Z, Raible F, Mollaaghababa R, Guyon JR, Wu CT, Bender W and Kingston RE: Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell. 98:37–46. 1999. View Article : Google Scholar : PubMed/NCBI
9	Levine SS, Weiss A, ErdjumentBromage H, Shao Z, Tempst P and Kingston RE: The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol. 22:6070–6078. 2002. View Article : Google Scholar : PubMed/NCBI
10	Kuzmichev A, Nishioka K, ErdjumentBromage H, Tempst P and Reinberg D: Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16:2893–2905. 2002. View Article : Google Scholar : PubMed/NCBI
11	Vincenz C and Kerppola TK: Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences. Proc Natl Acad Sci USA. 105:16572–16577. 2008. View Article : Google Scholar : PubMed/NCBI
12	Shinjo K, Yamashita Y, Yamamoto E, Akatsuka S, Uno N, Kamiya A, Niimi K, Sakaguchi Y, Nagasaka T, Takahashi T, et al: Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. Int J Cancer. 135:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
13	Scott CL, Gil J, Hernando E, TeruyaFeldstein J, Narita M, Martínez D, Visakorpi T, Mu D, Cordon-Cardo C, Peters G, et al: Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci USA. 104:5389–5394. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zhang XW, Zhang L, Qin W, Yao XH, Zheng LZ, Liu X, Li J and Guo WJ: Oncogenic role of the chromobox protein CBX7 in gastric cancer. J Exp Clin Cancer Res. 29:1142010. View Article : Google Scholar : PubMed/NCBI
15	Li J, Xu Y, Long XD, Wang W, Jiao HK, Mei Z, Yin QQ, Ma LN, Zhou AW, Wang LS, et al: Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer Cell. 25:118–131. 2014. View Article : Google Scholar : PubMed/NCBI
16	Klauke K, Radulović V, Broekhuis M, Weersing E, Zwart E, Olthof S, Ritsema M, Bruggeman S, Wu X, Helin K, et al: Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. Nat Cell Biol. 15:353–362. 2013. View Article : Google Scholar : PubMed/NCBI
17	Parris TZ, Danielsson A, Nemes S, Kovács A, Delle U, Fallenius G, Möllerström E, Karlsson P and Helou K: Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res. 16:3860–3874. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ: WHO Classification of Tumours of the Breast. 4th. IARC, WHO; 2012
19	Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T and Miyoshi Y: High Ki-67 expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer. Clin Breast Cancer. 15:204–211. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014. View Article : Google Scholar : PubMed/NCBI
21	Tubbs RR, Hicks DG, Cook J, DownsKelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, et al: Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: A single institution experience. Diagn Mol Pathol. 16:207–210. 2007. View Article : Google Scholar : PubMed/NCBI
22	Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J and Foukakis T: Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Res Treat. 147:407–414. 2014. View Article : Google Scholar : PubMed/NCBI
23	Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, et al: Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer. 105:272–280. 2011. View Article : Google Scholar : PubMed/NCBI
24	Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y and Iwase H: p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 8:R482006. View Article : Google Scholar : PubMed/NCBI
25	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
26	Remmele W and Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs subjective grading (IRS). Pathol Res Pract. 189:862–866. 1993. View Article : Google Scholar : PubMed/NCBI
27	Clermont PL, Sun L, Crea F, Thu KL, Zhang A, Parolia A, Lam WL and Helgason CD: Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: Initial evidence of an oncogenic role. Br J Cancer. 111:1663–1672. 2014. View Article : Google Scholar : PubMed/NCBI
28	Parris TZ, Aziz L, Kovács A, Hajizadeh S, Nemes S, Semaan M, Chen CY, Karlsson P and Helou K: Clinical relevance of breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma. BMC Cancer. 14:3242014. View Article : Google Scholar : PubMed/NCBI
29	Satijn DP, Olson DJ, van der Vlag J, Hamer KM, Lambrechts C, Masselink H, Gunster MJ, Sewalt RG, van Driel R and Otte AP: Interference with the expression of a novel human polycomb protein, hPc2, results in cellular transformation and apoptosis. Mol Cell Biol. 17:6076–6086. 1997. View Article : Google Scholar : PubMed/NCBI
30	Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, et al: Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. 6:39865–39876. 2015.PubMed/NCBI
31	Kerppola TK: Polycomb group complexes-many combinations, many functions. Trends Cell Biol. 19:692–704. 2009. View Article : Google Scholar : PubMed/NCBI
32	Di Croce L and Helin K: Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol. 20:1147–1155. 2013. View Article : Google Scholar : PubMed/NCBI
33	Piunti A, Rossi A, Cerutti A, Albert M, Jammula S, Scelfo A, Cedrone L, Fragola G, Olsson L, Koseki H, et al: Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication. Nat Commun. 5:36492014. View Article : Google Scholar : PubMed/NCBI
34	Zhen CY, Duc HN, Kokotovic M, Phiel CJ and Ren X: Cbx2 stably associates with mitotic chromosomes via a PRC2- or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes. Mol Biol Cell. 25:3726–3739. 2014. View Article : Google Scholar : PubMed/NCBI
35	van den Boom V, RozenveldGeugien M, Bonardi F, Malanga D, van Gosliga D, Heijink AM, Viglietto G, Morrone G, Fusetti F, Vellenga E and Schuringa JJ: Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells. Blood. 121:2452–2461. 2013. View Article : Google Scholar : PubMed/NCBI
36	van den Boom V, RozenveldGeugien M, Bonardi F, Malanga D, van Gosliga D, Heijink AM, Viglietto G, Morrone G, Fusetti F, Vellenga E and Schuringa JJ: Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells. Blood. 121:2452–2561. 2013. View Article : Google Scholar : PubMed/NCBI
37	Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
38	Zelnak AB, Nikolinakos P, Srinivasiah J, Jonas W, Pippas A, Liu Y, Li X, Torres M and O'Regan RM: Georgia Center for Oncology Research and Education: High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. Clin Breast Cancer. 15:31–36. 2015. View Article : Google Scholar : PubMed/NCBI
39	Kathawala RJ, Sodani K, Chen K, Patel A, Abuznait AH, Anreddy N, Sun YL, Kaddoumi A, Ashby CR Jr and Chen ZS: Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: A preclinical study. Mol Cancer Ther. 13:714–723. 2014. View Article : Google Scholar : PubMed/NCBI
40	Peng X, Cao P, He D, Han S, Zhou J, Tan G, Li W, Yu F, Yu J, Li Z and Cao K: MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int J Clin Exp Pathol. 7:6784–6791. 2014.PubMed/NCBI
41	Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T and Venkitaraman AR: Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene. 31:2450–2460. 2012. View Article : Google Scholar : PubMed/NCBI
42	Ruddock-D'Cruz NT, Prashadkumar S, Wilson KJ, Heffernan C, Cooney MA, French AJ, Jans DA, Verma PJ and Holland MK: Dynamic changes in localization of Chromobox (Cbx) family members during the maternal to embryonic transition. Mol Reprod Dev. 75:477–488. 2008. View Article : Google Scholar : PubMed/NCBI
43	Huynh H: Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma. Carcinogenesis. 25:1485–1494. 2004. View Article : Google Scholar : PubMed/NCBI
44	Reno EM, Haughian JM, Dimitrova IK, Jackson TA, Shroyer KR and Bradford AP: Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol. 39:21–29. 2008. View Article : Google Scholar : PubMed/NCBI